US Dry Age-Related Macular Degeneration (AMD) Market: Driving Innovation in Ophthalmic Therapeutics
The US Dry Age-Related Macular Degeneration (AMD) Market is a critical and rapidly evolving segment within the nation's advanced ophthalmic healthcare industry. Dry Age-Related Macular Degeneration (AMD) is the most prevalent form of AMD, a progressive degenerative eye disease that primarily affects the macula, the central part of the retina responsible for sharp, detailed vision. Characterized by the formation of drusen and the thinning of macular tissue, it leads to gradual central vision loss. While historically lacking specific pharmacological treatments, the market now includes newly approved therapies for Geographic Atrophy (GA), an advanced form of dry AMD, alongside diagnostic tools, nutritional supplements, and supportive care products. The demand is profoundly driven by the large and growing aging population, increased disease awareness, and significant investment in research and development for novel therapeutic interventions. Key players include leading pharmaceutical companies, biotechnology firms, medical device manufacturers, and a vast network of ophthalmic clinics and research institutions.
The robust US Dry Age-Related Macular Degeneration (AMD) Market growth is fundamentally propelled by a confluence of powerful factors. A primary catalyst is the expanding aging population in the United States. As the largest demographic segment at risk for AMD, the increasing number of individuals aged 65 and older directly correlates with a higher incidence and prevalence of the disease. The Population Reference Bureau projects a significant increase in Americans aged 65 and older, underscoring this demographic influence. Concurrently, significant advancements in diagnostic tools and increasing awareness of AMD are driving earlier diagnosis and more proactive management. This includes sophisticated imaging technologies like Optical Coherence Tomography (OCT) and fundus autofluorescence (FAF). The recent approval of novel therapies specifically for Geographic Atrophy (GA) has revolutionized the market, addressing a major unmet medical need and providing a new avenue for treatment. Furthermore, substantial investment in ophthalmic and retinal research by both public and private sectors, coupled with a robust pipeline of investigational drugs, continues to fuel market expansion. In essence, the US Dry Age-Related Macular Degeneration (AMD) Market plays a pivotal role in combating a leading cause of vision loss among the elderly and promises further innovation in vision preservation.
Pipeline Therapies and Market Dynamics
The US Dry Age-Related Macular Degeneration (AMD) Market is experiencing robust growth, primarily driven by the significant burden of the disease in an aging population, recent therapeutic breakthroughs, and a strong pipeline of innovative treatments. A primary and profoundly influential driver is the large and continuously growing aging population. The United States has a substantial demographic shift towards an older population, with individuals aged 65 and over being the primary group affected by AMD. This demographic trend ensures a steady increase in the patient pool requiring diagnosis, monitoring, and treatment for dry AMD.
Secondly, the recent approval of therapies for Geographic Atrophy (GA), an advanced form of dry AMD, has fundamentally transformed the market. For decades, there were no specific treatments for dry AMD, leaving a significant unmet medical need. The introduction of drugs like Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), which target the complement system, has provided the first options to slow the progression of GA. These approvals have created entirely new revenue streams and spurred further investment in dry AMD research.
The US Dry Age-Related Macular Degeneration (AMD) Market size is a substantial portion of the broader Age-Related Macular Degeneration (AMD) market. The global AMD market was valued at 11.42 billion in 2024 and is projected to reach 20.88 billion by 2033, exhibiting a CAGR of 6.94% from 2025 to 2033 for the global AMD Market forecast. The US dry AMD market prevalence, specifically for geographic atrophy (GA) in Medicare Advantage enrollees, was around 0.51% in 2021, and the prevalence of early-stage dry AMD was approximately 2.6% in 2021 for the same population. Approximately 11 million individuals in the United States are affected by AMD alone.
Key segments and factors influencing the overall US Dry Age-Related Macular Degeneration (AMD) Market share include:
By Disease Stage:
Early and Intermediate Dry AMD: Management primarily involves lifestyle modifications, nutritional supplements (AREDS/AREDS2 formulations), and regular monitoring.
Late-stage Dry AMD (Geographic Atrophy - GA): This segment has been revolutionized by the recent approval of complement inhibitors. This includes products like:
Syfovre (pegcetacoplan) by Apellis Pharmaceuticals: Approved by the FDA for GA.
Izervay (avacincaptad pegol) by Iveric Bio (now Astellas Pharma): Also approved by the FDA for GA.
By Product Type:
Pharmaceuticals: This is the fastest-growing segment, driven by the new GA treatments.
Nutritional Supplements: Over-the-counter vitamins and minerals (e.g., PreserVision AREDS 2 formula) remain a significant segment for slowing progression.
Diagnostic Devices: Include Optical Coherence Tomography (OCT), fundus photography, and microperimetry systems.
Low Vision Aids: Devices to help patients cope with central vision loss.
By End-User: Ophthalmic clinics, hospitals, and ambulatory surgical centers.
By Route of Administration: Intravitreal injections (for the new GA therapies) and oral supplements.
The US Dry Age-Related Macular Degeneration (AMD) Market forecast indicates sustained and accelerated growth, largely driven by the impact of newly approved therapies for GA and a robust pipeline of investigational drugs. Several companies are actively developing new treatments targeting various pathways involved in dry AMD pathology, including gene therapies, neuroprotective agents, and other complement inhibitors. The high unmet need, coupled with substantial research and development investments and an aging demographic, positions the US as a leader in the global dry AMD market, with a focus on innovative solutions to preserve vision.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com